B
Bull
Bull · 25%TSBX
$0.39
Szenariopreis
$0.355
+0.005 (+1.43%)Zum Schluss
Loading chart…
- High
- 0.365
- Open
- 0.350
- VWAP
- 0.36
- Vol
- 283.77K
- Mkt Cap
- 69.15M
- Low
- 0.350
- Amount
- 101.21K
- EV/EBITDA, TTM
- 0.57
Turnstone Biologics Corp. is a biotechnology company. The Company has been focused on the development of a differentiated approach to treating and curing patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy. It has discontinued all sponsored clinical studies evaluating TIDAL-01 for all indications, and pursuit of strategic alternatives to enhance and preserve stockholder value, which may include exploration and evaluation of strategic options like a merger, reverse merger, other business combinations, sale of assets, licensing, or other strategic transactions.
Bewertungskennzahlen
The current forward P/E ratio for Turnstone Biologics Corp (TSBX) is -1.58, compared to its 5-year average forward P/E of -0.83.
Alphio AI Price Scenarios for TSBX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
7.007-05GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMS, TSBX, BGFV on Behalf of Shareholders
7.006-30Globenewswire$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Turnstone Biologics Corp. (NASDAQ: TSBX)
8.506-27NASDAQ.COMXOMA To Acquire Turnstone Biologics For $0.34/Shr Plus Contingent Value Right
7.006-27PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRC, TSBX, DNOW on Behalf of Shareholders
8.506-27NewsfilterTurnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
TSBX FAQ — answered by Alphio AI
Turnstone Biologics Corp. is a biotechnology company. The Company has been focused on the development of a differentiated approach to treating and curing patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy. It has discontinued all sponsored clinical studies evaluating TIDAL-01 for all indications, and pursuit of strategic alternatives to enhance and preserve stockholder value, which may include exploration and evaluation of strategic options like a merger, reverse merger, other business combinations, sale of assets, licensing, or other strategic transactions. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.